Abstract 5949
Background
In hereditary cancers, disclosure of genetic testing and communication of genetic information to family members is crucial to manage their potential cancer risk. In Switzerland, according to privacy law, genetic information can be passed on to at-risk relatives only through the individual identified with the pathogenic mutation but 20-40% of at-risk family members remain unaware of relevant genetic information and less than 50% refer to genetic services. Healthcare providers have a relevant and challenging role in supporting family communication on genetics but this is still limited and not clear. The aim of the study is to explore how mutation carriers’ communicate about genetics within family members and how this is concretely supported in clinical practice.
Methods
Ongoing qualitative study. Data are collected with distinct focus groups with a purposeful sample of about 30 hereditary breast and ovarian cancer (HBOC) and Lynch syndrome (LS) mutation carriers and 30 relatives from three linguistic areas of Switzerland. The sample is diversified in terms of gender, clinical history and attitude towards family communication. Interviews with 15 healthcare providers routinely involved in genetic counselling are performed, too. Data collection and data analysis continue iteratively until data saturation according to constant comparative method.
Results
Qualitative data from focus groups and interviews show that family communication of genetic information is complex, affected by a wide variety of factors and closely interconnected with the disease condition. Communication to family members takes place according to different patterns and changes along the trajectory of life and illness. Healthcare providers play an important role.
Conclusions
Supporting communication of genetic information within family members is a challenging aspect of genetic healthcare and risk communication. Research about communication on genetics is timely and essential to implement interventions that can enhance cascade testing and genetic information for cancer prevention and control in clinical practice and for multilevel public health initiatives.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1885 - Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: an open label, non randomized study
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
5259 - Integrative RNAseq and Target panel sequencing reveals common and distinct innate and adaptive resistance mechanisms to BRAF inhibitors
Presenter: Phil Cheng
Session: Poster Display session 3
Resources:
Abstract
5619 - Effective treatment with T-VEC monotherapy in Stage IIIB/C-IVM1a Melanoma of the Head & Neck Region
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
5666 - Re-introduction of T-VEC Monotherapy in Recurrent Stage IIIB/C-IVM1a melanoma is effective
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
4117 - Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): subgroup analysis of the phase 3 OPTiM study
Presenter: Mark Middleton
Session: Poster Display session 3
Resources:
Abstract
5303 - Real Life Use of Talimogene Laherparepvec in Melanoma in Centers in Austria and Switzeland
Presenter: Christoph Hoeller
Session: Poster Display session 3
Resources:
Abstract
4130 - Outcomes of advanced melanoma patients who discontinued pembrolizumab (pembro) after complete response (CR) in the French early access program (EAP)
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
2050 - Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)
Presenter: Sarah Knispel
Session: Poster Display session 3
Resources:
Abstract
1618 - Comparative-Effectiveness of Pembrolizumab vs. Nivolumab for Patients with Metastatic Melanoma
Presenter: Justin Moser
Session: Poster Display session 3
Resources:
Abstract
3556 - Long-term efficacy of combination nivolumab and ipilimumab for first-line treatment of advanced melanoma: a network meta-analysis
Presenter: Peter Mohr
Session: Poster Display session 3
Resources:
Abstract